A Phase I Study of PLX51107 (A Novel Bromodomain Inhibitor) in Combination with Azacytidine for Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia (AML)
MD Anderson Study Status
Azacitidine, BRD4 Inhibitor PLX51107
This phase I trial studies the side effects and best dose of PLX51107 and how well it works with azacitidine in treating patients with acute myeloid leukemia or myelodysplastic syndrome. PLX51107 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving PLX51107 and azacitidine may work better than azacitidine alone in treating patients with acute myeloid leukemia or myelodysplastic syndrome.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.